I-MAB ADR IMAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IMAB is a good fit for your portfolio.
News
-
I-Mab Announces Participation at Jefferies and Piper Conferences in November
-
Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)
-
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023
-
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023
-
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503
-
Thinking about buying stock in ALX Oncology Holdings, RedHill Biopharma, Freeline Therapeutics Holdings, Terawulf, or I-Mab?
-
Theft in open court: How a fight over lifesaving drugs led to charges of brazen industrial espionage
Trading Information
- Previous Close Price
- $1.52
- Day Range
- $1.50–1.58
- 52-Week Range
- $1.17–7.14
- Bid/Ask
- $1.55 / $1.56
- Market Cap
- $128.89 Mil
- Volume/Avg
- 122,256 / 712,827
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 44.38
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 2.53%
Company Profile
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 318
- Website
- https://www.i-mabbiopharma.com
Valuation
|
Metric
|
IMAB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.37 |
Price/Sales | 44.38 |
Price/Cash Flow | — |
Price/Earnings
IMAB
Financial Strength
|
Metric
|
IMAB
|
|---|---|
Quick Ratio | 4.60 |
Current Ratio | 4.64 |
Interest Coverage | −10,013.98 |
Quick Ratio
IMAB
Profitability
|
Metric
|
IMAB
|
|---|---|
Return on Assets (Normalized) | −32.82% |
Return on Equity (Normalized) | −44.04% |
Return on Invested Capital (Normalized) | −44.44% |
Return on Assets
IMAB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ttq | $445.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nhvglq | $91.1 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gkqghnt | $91.1 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Krzmk | $40.7 Bil | |
MRNA
| Moderna Inc | Nwhm | $30.7 Bil | |
ARGX
| argenx SE ADR | Pbt | $27.7 Bil | |
BNTX
| BioNTech SE ADR | Gbxf | $24.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Slrrc | $22.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Lzypy | $17.7 Bil | |
INCY
| Incyte Corp | Wlxrsz | $12.4 Bil |